Scroll

vismodegib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
SMO receptor antagonists	4227	879085-55-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: erivedge vismodegib GDC-0449 RG3616	inhibits the hedgehog pathway and ABC transporters; has antineoplastic activity Molecular weight: 421.29 Formula: C19H14Cl2N2O3S CLOGP: 2.74 LIPINSKI: 0 HAC: 5 HDO: 1 TPSA: 76.13 ALOGS: -5.39 ROTB: 4 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

erivedge
vismodegib
GDC-0449
RG3616

inhibits the hedgehog pathway and ABC transporters; has antineoplastic activity

Molecular weight: 421.29
Formula: C19H14Cl2N2O3S
CLOGP: 2.74
LIPINSKI: 0
HAC: 5
HDO: 1
TPSA: 76.13
ALOGS: -5.39
ROTB: 4

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Show entries

Search:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	4	Hosey CM, Chan R, Benet LZ
t_half (Half-life)	245 hours	Lombardo F, Berellini G, Obach RS
Vd (Volume of distribution)	0.23 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.01 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.01 %	Lombardo F, Berellini G, Obach RS
S (Water solubility)	0.00 mg/mL	Bocci G, Oprea TI, Benet LZ

Showing 1 to 6 of 6 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Jan. 30, 2012	FDA	GENENTECH
July 12, 2013	EMA	Roche Registration Ltd

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Muscle spasms	517.23	36.89	213	2796	155937	63330076
Dysgeusia	416.82	36.89	133	2876	46577	63439436
Alopecia	387.88	36.89	223	2786	337313	63148700
Ageusia	335.91	36.89	86	2923	13642	63472371
Death	163.18	36.89	137	2872	374244	63111769
Weight decreased	127.94	36.89	105	2904	276693	63209320
Decreased appetite	117.53	36.89	96	2913	250956	63235057
Squamous cell carcinoma	66.15	36.89	22	2987	8610	63477403
Fatigue	46.72	36.89	118	2891	887910	62598103
No adverse event	43.24	36.89	26	2983	41379	63444634

Showing 1 to 10 of 11 entries

Previous1 2Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Muscle spasms	1092.43	33.13	393	4081	74608	34877849
Alopecia	829.63	33.13	244	4230	24111	34928346
Ageusia	690.01	33.13	176	4298	10132	34942325
Dysgeusia	553.91	33.13	183	4291	26314	34926143
Weight decreased	208.68	33.13	175	4299	176126	34776331
Squamous cell carcinoma	157.04	33.13	58	4416	11417	34941040
Decreased appetite	135.20	33.13	134	4340	166258	34786199
Death	117.32	33.13	193	4281	397856	34554601
Fatigue	78.49	33.13	156	4318	370497	34581960
Taste disorder	68.76	33.13	28	4446	7127	34945330

Showing 1 to 10 of 16 entries

Previous1 2Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Muscle spasms	932.72	31.60	366	4763	174364	79564895
Dysgeusia	566.62	31.60	190	4939	56987	79682272
Ageusia	545.36	31.60	140	4989	16492	79722767
Alopecia	455.75	31.60	243	4886	231112	79508147
Weight decreased	188.09	31.60	166	4963	355032	79384227
Death	183.12	31.60	202	4927	566312	79172947
Decreased appetite	173.20	31.60	156	4973	342262	79396997
Squamous cell carcinoma	154.48	31.60	52	5077	15570	79723689
Fatigue	86.45	31.60	186	4943	929541	78809718
Neutrophil count decreased	61.89	31.60	50	5079	93909	79645350

Showing 1 to 10 of 16 entries

Previous1 2Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	L01XJ01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Hedgehog pathway inhibitors
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:50905	teratogeno
CHEBI has role	CHEBI:66908	SMO receptor antagonists
CHEBI has role	CHEBI:140921	Hedgehog pathway inhibitors
FDA EPC	N0000184149	Hedgehog Pathway Inhibitor
FDA MoA	N0000184148	Smoothened Receptor Antagonists

Showing 1 to 7 of 7 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID
Basal cell carcinoma of skin	indication	254701007
Pregnancy, function	contraindication	289908002
Hypericum perforatum extract	contraindication	412515006
Breastfeeding (mother)	contraindication	413712001

Showing 1 to 4 of 4 entries

Previous1Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.07	acidic
pKa2	4.25	Basic

Orange Book patent data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
150MG	ERIVEDGE	GENENTECH	N203388	Jan. 30, 2012	RX	CAPSULE	ORAL	9790183	Sept. 2, 2025	METHOD OF USING VISMODEGIB TO TREAT BASAL CELL CARCINOMA
150MG	ERIVEDGE	GENENTECH	N203388	Jan. 30, 2012	RX	CAPSULE	ORAL	9278961	Dec. 15, 2028	METHOD OF USING VISMODEGIB TO TREAT CANCER IN A MAMMAL

Showing 1 to 2 of 2 entries

Previous1Next

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Smoothened homolog	GPCR	Q99835	SMO_HUMAN	INHIBITOR	Ki	7.79	CHEMBL	CHEMBL
ATP-binding cassette sub-family G member 2	Transporter	Q9UNQ0	ABCG2_HUMAN		IC50	5.85	CHEMBL
Sonic hedgehog protein	Enzyme	Q15465	SHH_HUMAN		IC50	7.82	CHEMBL
Sonic hedgehog protein	Enzyme		SHH_MOUSE		IC50	8.52	CHEMBL
Smoothened homolog	GPCR		SMO_MOUSE		IC50	8.30	CHEMBL

Showing 1 to 5 of 5 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
014152	NDDF
1242987	RXNORM
187095	MMSL
24776445	PUBCHEM_CID
25X868M3DS	UNII
28293	MMSL
4031330	VANDF
6975	IUPHAR_LIGAND_ID
703812008	SNOMEDCT_US
703813003	SNOMEDCT_US

Showing 1 to 10 of 19 entries

Previous1 2Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
ERIVEDGE	HUMAN PRESCRIPTION DRUG LABEL	1	50242-140	CAPSULE	150 mg	ORAL	NDA	31 sections
ERIVEDGE	HUMAN PRESCRIPTION DRUG LABEL	1	50242-140	CAPSULE	150 mg	ORAL	NDA	31 sections

Showing 1 to 2 of 2 entries

Previous1Next